TOKEN2049
8.7.2022 10:45:13 CEST | Business Wire | Press release
TOKEN2049 , Asia’s premier crypto conference, has announced a new batch of title sponsors and speakers for its upcoming Singapore edition which will be running from 28 to 29 September. This year marks the conference’s Singapore debut, making for a thrilling week of activities as some of the world’s most pioneering projects gather at what’s set to be the crypto industry’s first major in-person event in Asia ahead of the Formula 1 Singapore Grand Prix 2022 race weekend.
In recognition of growing excitement around the event, TOKEN2049 Singapore’s roster of sponsors grew to 200 firms within the last three weeks. New additions to its line-up of title sponsors include next-generation crypto spot and derivatives trading exchange OKX ; leading hardware wallet manufacturer Ledger ; one of the world’s largest crypto exchanges Kucoin ; Hong Kong-based digital asset exchange AAX ; the world’s largest cryptocurrency derivatives copy trade platform Bitget ; and homegrown Singaporean crypto exchange Coinhako, which secured its major payment institution license earlier this year.
A notable addition to this year's Title Sponsor lineup is a leading South Korean game company WEMADE , best known as the creator of leading MMORPG series Legend of Mir which sees over 120 million players worldwide. WEMADE has been servicing blockchain games since 2020, and currently 14 titles are onboarded on its platform WEMIX , including MIR4, the number 1 play-to-earn MMORPG.
A WEMADE spokesperson said: “With the industry growing at unprecedented levels and the amount of innovation it’s channeling globally, TOKEN2049 and the important conversations that it will catalyse couldn’t have come at a better time.”
As the flagship event of Asia Crypto Week , the conference is expected to draw 3,000 attendees from across the world. This year’s impressive line-up includes Stani Kulechov, Founder and CEO of AAVE, the leading open-source and non-custodial liquidity protocol; Haseeb Kureshi, Managing Partner of Dragonfly Capital; and Eli Ben-Sasson, Co-Founder and President of Starkware and co-inventor of zkSTARK, the privacy-preserving cryptographic proof.
Panels and keynotes at the event are set to address a broad agenda — from the evolving regulatory landscape and institutional investment trends to the rise of the metaverse, Web3, and what this will ultimately mean for the industry as mainstream awareness intensifies.
The Singapore event is set to be the largest in TOKEN2049’s history amid the token economy’s huge potential to transform industries and communities around the world. As a testament to growing interest among broader mainstream audiences, McLaren Racing Formula One driver Daniel Ricciardo, the new brand ambassador for world-leading crypto trading app and web3 platform OKX, will also be speaking at the conference ahead of Sunday’s Singapore Grand Prix 2022 race, sharing his views on digital assets and the evolving nature of fan engagement.
Additional speakers at this year’s conference include Justin Sun, Founder of Tron, the open-source, Proof-of-Stake blockchain platform and Sandeep Nailwal, Co-Founder of Polygon, the decentralised Ethereum scaling platform.
Commenting on the 200-sponsor milestone, Raphael Strauch, Founder of TOKEN2049 said: “The numbers don’t lie, and this overwhelming interest and energy only bode well for the industry. I’m thrilled to see the conversations and solutions that will emerge from Singapore this September.”
As part of Asia Crypto Week, attendees can expect to attend a full line-up of side events, including Pantera Blockchain Summit Asia, Milken Institute Asia Summit, and Algorand AVM Singapore, with many more to be announced in the coming weeks.
For more information and continued updates on TOKEN2049 Singapore, please visit: https://www.asia.token2049.com/
About TOKEN2049:
TOKEN2049 is a premier Web3 event, organised annually in Singapore and London, where decision-makers in the global crypto ecosystem connect to exchange ideas, network, and shape the industry. TOKEN2049 is a global meeting place for entrepreneurs, institutions, industry insiders, investors, and those with a strong interest in the crypto and blockchain industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005567/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Opening of Jayasom Wellness Resort Advancing AMAALA’s Wellness Vision16.9.2026 14:23:00 CEST | Press release
The latest addition to AMAALA’s wellness ecosystem integrates evidence-based practices with Arab and Eastern healing practices complemented by personalized wellness programs Red Sea Global (RSG), the regenerative tourism developer, has opened Jayasom Wellness Resort AMAALA, bringing a distinctive holistic health offering to the destination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916231950/en/ Outdoor relaxation area at Jayasom Wellness Resort AMAALA, where serene design and sea-facing spaces create a setting for rest and renewal. Designed by Heah & Co., with interiors by Studio Carter, Jayasom Wellness Resort AMAALA is located on Triple Bay’s largest cove and comprises 153 keys alongside 24 residences. The resort forms part of AMAALA’s secluded wellness core on the Red Sea coast, where nature and hospitality come together in a setting designed for reflection and renewal. “As we launch the first Jayasom globally, w
Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth16.9.2026 14:01:00 CEST | Press release
AGA clinical trial to begin in Fall 2026 led by David Pariser, MD, FACP, FAAD, former President of the American Academy of Dermatology and Principal Investigator in more than 450 dermatology clinical trialsRubedo’s RLS-1496, the first and only GPX4 modulator currently in clinical trials, demonstrates superior hair follicle restoration in human ex vivo androgenetic alopecia (AGA) model, matching or outperforming finasteride; findings consistent with dual SenoAdaptive mechanism that activates dormant hair follicle Rubedo Life Sciences, Inc. (Rubedo) today announced a new clinical study of investigational RLS-1496 in patients with androgenetic alopecia (AGA), beginning October 2026, with initial data expected in the first half of 2027. The study marks the first-ever clinical evaluation of a GPX4 modulator in hair loss, extending the program that established RLS-1496 as the world’s first GPX4 modulator to enter human clinical trials of any kind. This press release features multimedia. View
NetApp and Tampa Bay Buccaneers Partner to Enable Data-Driven Operational Excellence16.9.2026 14:00:00 CEST | Press release
New sponsorship expands NetApp’s presence across the NFL, delivering trusted data, intelligence, and the ability to perform in critical moments NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that they have been named an Official Partner of the Tampa Bay Buccaneers. This new relationship builds on NetApp’s status as the Official Intelligent Data Infrastructure Partner of the NFL, helping the league and its teams quickly and confidently access, manage, and activate their data. The Buccaneers will leverage NetApp technology to support the experience for Buccaneers fans in the stadium on game days and beyond. “NetApp will serve as a trusted technology partner that will help us elevate the customer experience for all Buccaneers fans,” said Buccaneers Chief Commercial Officer Atul Khosla. “Reliable and secure access to data plays an essential role in the overall game day experience at Raymond James Stadium. NetApp’s industry-leading intelligent data infr
Unique Australian Clay: Multi Minerals Australia’s Non-antibiotic Solution for Poultry Production16.9.2026 13:44:00 CEST | Press release
Multi Minerals Australia, a leading mining company, announced a one-of-a-kind formulation of Australian clays which has proven it can reshape the global poultry feed economic landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916711777/en/ Unique, non-antibiotic clay stockfeed component and production enhancer from Multi Minerals Australia. Sourced from its one-of-a-kind geological deposit. Proven results. Worldwide distribution. Potential applications and lower cost benefits to a range of commercial animal production, particularly poultry. Expressions of interest sought. Numerous scientific, clinical, and commercial producer validations have demonstrated the product’s significant benefits; including the reduction of feed costs; improvements in: growth; meat yield; feed conversion; resistance to heat stress; eggshell quality and production: reduced inflammation and mortality in layer and broiler production. It has
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 202616.9.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 and will participate in a fireside chat at 1:00pm ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/fAK4ioHxQNLX5A2utMmqiy/2vkuNBQpn65oayAPDgU4rZ A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom